Benzodiazepine:sedative overdoseMANAGEMENT

TOXICOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

533 items

☷ Legend

01Approach to the Critical Patient/attcp87

Immediate priorities

›Stabilization priorities

›If apnea

›Bag valve mask ventilation

›Advanced airway for persistent apnea or refractory hypoventilation

›If hypoxemia

›Supplemental oxygen

›Positive pressure ventilation as needed

›If hypotension

›Isotonic crystalloid bolus

›Vasopressor infusion if fluid refractory

›If bradycardia with instability

›Atropine per ACLS

›Transcutaneous pacing if refractory

›If hypoglycemia

›Dextrose bolus

›Continuous infusion if recurrent

›If seizure activity

›Benzodiazepines for active seizures

›Second line antiseizure therapy if refractory

›Temperature

›Active warming for hypothermia

›Passive cooling for hyperthermia from coingestants

Toxidrome recognition

›Sedative hypnotic toxidrome

›CNS depression

›Somnolence to coma

›Slurred speech

›Ataxia

›Respiratory depression

›Hypoventilation

›Hypercapnia

›Hemodynamics

›Usually stable in isolated benzodiazepine exposure

›Hypotension suggests coingestion or alternate diagnosis

›Pupils

›Normal to mildly miotic

›Marked miosis suggests opioid coingestion

›Skin

›Usually normal

›Diaphoresis suggests alternate toxidrome

Key decision points

›High risk triggers

›Mixed ingestion concern

›Alcohol

›Opioids

›Tricyclic antidepressants

›Barbiturates

›Z drugs

›Gamma hydroxybutyrate

›Long acting agent concern

›Diazepam

›Chlordiazepoxide

›Clonazepam

›Sustained release coingestant concern

›Extended release sedatives or other agents

›Vulnerable physiology

›COPD

›OSA

›Frailty

›Pregnancy

›Trauma risk from fall

›Head strike

›Anticoagulation

Monitoring and targets

›Monitoring

›Continuous pulse oximetry

›Oxygen saturation target per local practice

›Escalation if persistent desaturation

›Cardiac monitor

›Dysrhythmia detection

›QT prolongation screening if coingestants

›Capnography

›Early hypoventilation detection

›Ventilation target

›End tidal CO2 trend normalization

›Frequent mental status reassessment

›Airway protective reflexes

›Trend toward awakening

›Temperature monitoring

›Hypothermia detection

›Aspiration pneumonia risk with hypothermia

Antidote posture

›Flumazenil posture

›Avoid routine use in undifferentiated overdose

›Seizure risk in chronic benzodiazepine use

›Seizure risk in mixed ingestion with proconvulsants

›Consider only in select scenarios

›Iatrogenic sedation reversal with airway risk

›Known isolated benzodiazepine ingestion

›No seizure history

›No proconvulsant coingestion concern

02History/hx60

Exposure characterization

›Exposure details

›Agent

›Benzodiazepine name if known

›Nonbenzodiazepine hypnotic name if known

›Barbiturate name if known

›Dose

›Tablets or mg estimate

›Maximum possible dose

›Time

›Last known well time

›Time of ingestion estimate

›Route

›Oral

›Intranasal

›Intravenous

›Formulation

›Immediate release

›Extended release

›Coingestants

›Alcohol

›Opioids

›Antidepressants

›Antipsychotics

›Antihistamines

›Muscle relaxants

›Gamma hydroxybutyrate

Baseline risk modifiers

›Patient factors

›Chronic benzodiazepine use

›Daily use

›High dose use

›Seizure history

›Epilepsy

›Prior withdrawal seizures

›Substance use disorder history

›Alcohol dependence

›Sedative hypnotic dependence

›Pulmonary disease

›COPD

›OSA

›Renal or hepatic disease

›Reduced clearance risk

›Pregnancy status

›Gestational age if known

Symptom timeline and context

›Clinical course

›Progressive somnolence

›Vomiting

›Falls

›Witnessed apnea

›Snoring respirations

›Seizures

›Chest symptoms suggesting aspiration

›Medication access

›Prescribed home benzodiazepines

›Recent prescription refill

›Recent anesthesia or procedural sedation

PITFALLS

›Pitfalls

›Isolated benzodiazepine overdose rarely causes severe respiratory failure

›Severe respiratory depression suggests opioid or other CNS depressant coingestion

›Paradoxical agitation possible in some benzodiazepines and in pediatrics

›Flumazenil can precipitate seizures and withdrawal in dependent patients

03Physical Exam/exam50

Core exam

›Primary survey findings

›Airway

›Gag reflex presence

›Secretions and vomitus

›Breathing

›Respiratory rate

›Work of breathing

›Breath sounds

›Circulation

›Blood pressure

›Heart rate

›Perfusion

›Disability

›GCS

›Pupillary size and reactivity

›Tone and reflexes

›Exposure

›Trauma signs

›Temperature

Toxidrome focused findings

›Sedation pattern

›Somnolence with arousability

›Dysarthria

›Ataxia

›Nystagmus

›Respiratory pattern

›Hypoventilation

›Snoring respirations

›Apnea episodes

›Alternative toxidrome clues

›Marked miosis

›Opioid coingestion concern

›Anticholinergic features

›Dry skin

›Urinary retention

›Sympathomimetic features

›Diaphoresis

›Agitation

Trauma and complications

›Complications screen

›Aspiration evidence

›Crackles

›Hypoxemia

›Rhabdomyolysis risk

›Prolonged down time

›Muscle tenderness

›Pressure injury risk

›Prolonged immobility

›PITFALLS

›Normal pupils does not exclude significant sedation

›Normal vital signs does not exclude impending hypoventilation

›Hypothermia can mimic deeper coma

04Differential Diagnosis/ddx44

Life threatening and must not miss

›Critical differentials

›Opioid toxicity

›ICD-10 T40 series poisoning

›Alcohol intoxication

›ICD-10 F10.129

›Carbon monoxide exposure

›ICD-10 T58

›Hypoglycemia

›ICD-10 E16.2

›Intracranial hemorrhage

›ICD-10 I61

›Ischemic stroke

›ICD-10 I63

›CNS infection

›ICD-10 G00, G03

›Sepsis

›ICD-10 A41

›Hypoxia or hypercapnia from COPD exacerbation

›ICD-10 J44.1

Toxin and medication mimics

›Toxicologic mimics

›Barbiturate toxicity

›ICD-10 T42.3 poisoning

›Z drug toxicity

›ICD-10 T42.7 poisoning

›Gamma hydroxybutyrate intoxication

›SNOMED CT concept for GHB poisoning

›Antipsychotic toxicity

›ICD-10 T43.5 poisoning

›Tricyclic antidepressant toxicity

›ICD-10 T43.0 poisoning

›Antihistamine toxicity

›ICD-10 T45.0 poisoning

›Clonidine toxicity

›ICD-10 T46.5 poisoning

Coding anchors

›Primary diagnosis coding

›Poisoning by benzodiazepines

›ICD-10 T42.4X1A accidental

›ICD-10 T42.4X2A intentional self harm

›ICD-10 T42.4X4A undetermined

›Toxic effect of unspecified sedative hypnotic

›ICD-10 T42.7X1A accidental

›SNOMED CT coding

›Benzodiazepine poisoning

›Drug induced respiratory depression

05Laboratory Tests/lt41

Core labs

›Baseline laboratory evaluation

›Point of care glucose

›Immediate correction threshold per local practice

›Electrolytes with creatinine

›Sodium mmol/l

›Potassium mmol/l

›Bicarbonate mmol/l

›Creatinine umol/l

›Venous blood gas

›pH

›pCO2 mmHg

›HCO3 mmol/l

›Complete blood count for infection or bleeding concern

›Leukocytosis interpretation caution

›Hemoglobin trend if trauma concern

Tox directed labs

›Toxicology labs

›Acetaminophen level for unknown ingestion

›Time from ingestion dependent interpretation

›Salicylate level for unknown ingestion

›Mixed respiratory alkalosis and metabolic acidosis clue

›Ethanol level when available

›Additive CNS depression risk

›Urine drug screen

›Limited utility for acute management

›False positives and false negatives

›Creatine kinase for prolonged down time concern

›Rhabdomyolysis risk stratification

›Lactate for shock or seizure concern

›Persistent elevation suggests alternate diagnosis

Complication labs

›Complication assessment

›Liver enzymes for suspected hepatic dysfunction or acetaminophen coingestion

›AST

›ALT

›Pregnancy test in patients with uterus of childbearing potential

›Serum preferred if high stakes decision making

›Troponin for chest pain or ischemia concern

›Alternate diagnosis detection

PITFALLS

›Limitations

›Benzodiazepine serum levels rarely guide management

›Standard urine screens may miss some benzodiazepines and many nonbenzodiazepine sedatives

›Normal early VBG does not exclude later hypoventilation in long acting ingestions

06Diagnostic Tests/dt36

Scoring Systems

›Clinical scales

›Glasgow Coma Scale

›Trend over time for trajectory

›Intubation consideration trigger when declining

›Richmond Agitation Sedation Scale

›Sedation depth monitoring

›Target for safe observation

›Clinical Opioid Overdose suspicion score surrogate

›Miosis

›Bradypnea

›Response to naloxone

MRI

›MRI brain indications

›Persistent altered mental status without clear tox explanation

›Focal neurologic deficit

›Suspected posterior circulation stroke with nondiagnostic CT

›Seizure with persistent deficit

›MRI constraints

›Unstable airway or ventilation

›Need for continuous monitoring compatibility

›CT head indications

›Head trauma or unwitnessed fall

›Anticoagulant use

›Persistent coma beyond expected drug kinetics

›Focal neurologic findings

›CT chest indications

›Aspiration pneumonitis pneumonia concern

›Unexplained hypoxemia

Ultrasound

›Point of care ultrasound uses

›Lung ultrasound for aspiration or pulmonary edema concern

›B lines pattern

›Consolidation pattern

›Cardiac ultrasound for shock concern

›Gross LV function

›Pericardial effusion

›IVC assessment adjunct in hypotension

›Volume responsiveness adjunct only

07Disposition/dispo31

Level of care decisions

›ICU indications

›Ongoing ventilatory support

›Recurrent apnea

›Persistent hypercapnia despite support

›Hemodynamic instability

›Refractory hypothermia

›Ward or monitored bed indications

›Moderate sedation requiring prolonged observation

›Long acting ingestion with delayed peak concern

›Aspiration pneumonitis requiring oxygen

›ED observation indications

›Stable vital signs

›Improving mental status trend

›No coingestant red flags

Discharge criteria

›Safe discharge criteria

›Awake and oriented at baseline

›Ambulation at baseline

›Tolerating oral intake

›Normal ventilation without supplemental oxygen

›No delayed effect concern based on agent and time

›Reliable supervision and follow up

Consultation and transfer

›Consultation triggers

›Poison center or clinical toxicology consult

›Mixed ingestion concern

›Flumazenil consideration

›Barbiturate concern

›Critical care consult

›Airway support need

›Vasopressor requirement

›Psychiatry consult when indicated by clinical context

›Safety assessment and disposition planning

08Treatment/t82

Supportive care

›Core supportive treatment

›Airway positioning

›Lateral recovery position for vomiting risk

›Suction setup

›Oxygen and ventilation support

›Nasal cannula for mild hypoxemia

›Noninvasive ventilation for hypercapnia with intact airway reflexes

›Intubation for apnea or inability to protect airway

›Fluids and hemodynamics

›Isotonic crystalloid bolus

›Norepinephrine infusion for shock

›Start low dose per local protocol

›Titrate to MAP target

›Central access if escalating dose

›Temperature management

›Active warming for hypothermia

›Warmed IV fluids if moderate to severe hypothermia

Decontamination

›Gastrointestinal decontamination

›Activated charcoal considerations

›Within 1 hour for substantial ingestion with protected airway

›Avoid if altered mental status without protected airway

›Avoid if imminent intubation not planned

›Whole bowel irrigation

›Rare role

›Consider only for massive sustained release coingestion with toxicology guidance

Antidotes and reversal agents

›Flumazenil

›Indications

›Iatrogenic benzodiazepine sedation with clinically significant respiratory depression

›Known isolated benzodiazepine ingestion with high confidence

›Contraindications

›Chronic benzodiazepine use or dependence

›Seizure disorder

›Mixed ingestion with proconvulsants

›Tricyclic antidepressant exposure concern

›Adult dosing

›Initiate 0.2 mg IV over 15 seconds

›Repeat 0.2 mg IV every 1 minute if needed

›Maximum 1 mg total for initial reversal attempt

›Pediatrics dosing

›Initiate 0.01 mg/kg IV

›Maximum 0.2 mg per dose

›Repeat every 1 minute if needed

›Maximum 0.05 mg/kg or 1 mg total

›Post reversal monitoring

›Resedation risk

›Observation length based on agent half life

›Repeat dosing requirement evaluation

›Seizure readiness

›Immediate seizure management plan

›Naloxone for suspected opioid coingestion

›Trial dosing

›Low dose IV titration for ventilation improvement

›Escalate dosing if no response and high suspicion

›Monitoring after response

›Renarcotization risk with long acting opioids

Seizure and agitation management

›Seizure management

›Benzodiazepine first line for active seizures

›Lorazepam IV dosing per local protocol

›Midazolam IM or IN if no IV access

›Second line agents

›Levetiracetam dosing per local protocol

›Valproate avoidance in pregnancy when possible

›Refractory status epilepticus

›Intubation with continuous infusion sedatives per ICU protocol

›Agitation paradoxical reaction

›Nonpharmacologic deescalation

›Antipsychotic use with QT monitoring when needed

Barbiturate specific pathway

›Barbiturate toxicity pathway

›Alkalinization for phenobarbital with toxicology guidance

›Sodium bicarbonate infusion

›Titrate urine pH target per protocol

›Potassium repletion to enable alkalinization

›Extracorporeal removal consideration

›Hemodialysis for severe phenobarbital with shock or coma

›Toxicology consult for thresholds

Monitoring during treatment

›Reassessment cadence

›Frequent respiratory reassessment

›Capnography trend

›VBG repeat if worsening ventilation

›Aspiration monitoring

›Lung exam trend

›Imaging if hypoxemia or fever develops

09Special Populations/sp32

Pregnancy

›Pregnancy considerations

›Maternal resuscitation priority

›Oxygenation and ventilation optimization

›Left lateral uterine displacement if late pregnancy

›Medication safety

›Flumazenil use only with strong indication and toxicology input

›Avoid valproate for seizures when alternatives available

›Fetal considerations

›Continuous fetal monitoring when viable gestational age and maternal instability

›Obstetrics consult for significant overdose

Geriatric

›Geriatric considerations

›Increased sensitivity

›Lower doses causing deeper sedation

›Higher fall risk

›Delayed clearance

›Hepatic metabolism reduction

›Drug accumulation with long acting agents

›Disposition bias toward observation

›Baseline cognitive impairment confounding

›Higher aspiration risk

Pediatrics

›Pediatric considerations

›Small ingestion risk

›Single tablet potentially significant in toddlers

›Paradoxical agitation

›Disinhibition

›Need for safe environment and monitoring

›Weight based dosing

›Flumazenil dosing by kg when indicated

›Airway equipment sizing readiness

›Safeguarding context

›Unsupervised access evaluation

›Social work involvement when needed

10Background/b35

Epidemiology

›Epidemiology

›Benzodiazepines common contributor to polysubstance sedation presentations

›Severe outcomes more likely with coingestants

›Alcohol

›Opioids

›Older adults higher risk of falls and delirium with benzodiazepines

Pathophysiology

›Pathophysiology

›Benzodiazepines

›Positive allosteric modulation of GABA A receptor

›Increased chloride conductance

›Enhanced inhibitory neurotransmission

›Z drugs

›GABA A receptor effects with relative selectivity

›Similar sedation and amnesia profile

›Barbiturates

›GABA A receptor agonism

›Greater respiratory depression risk than benzodiazepines

›Additive depression with other CNS depressants

›Synergistic respiratory depression with opioids and alcohol

Therapeutic Considerations

›Treatment principles

›Supportive care as mainstay for isolated benzodiazepine exposure

›Airway and ventilation support prevents morbidity

›Flumazenil risk benefit balance

›Reversal benefit in select iatrogenic cases

›Seizure and withdrawal risk in dependence or mixed ingestion

›Decontamination limited by airway risk

›Activated charcoal only with protected airway

›Observation duration based on pharmacokinetics

›Longer for long acting agents

›Longer with hepatic impairment

›Guideline posture and evidence labels

›ACEP style evidence labeling

›Routine flumazenil avoidance in undifferentiated overdose aligns with ACEP Level C consensus

›Airway and ventilation support aligns with Class I resuscitation principles

›Activated charcoal only with protected airway aligns with Class IIb toxicology consensus

11Patient Discharge Instructions/pdi27

copy discharge instructions

›Discharge instructions

›Diagnosis explanation

›Sedative medication exposure with slowed thinking and breathing risk

›Next 24 hours safety

›No driving

›No alcohol

›No cannabis

›No sedating medications unless prescribed and reviewed

›Responsible adult observation if available

›Hydration and nutrition

›Fluids as tolerated

›Light meals as tolerated

›Return to ED now for

›Trouble breathing

›Blue lips or severe sleepiness

›Repeated vomiting

›Chest pain

›Fever or worsening cough

›Confusion that worsens

›Fainting or new weakness

›Seizure

›Follow up

›Primary care within 1 to 3 days

›Medication review for sedatives and interactions

›Prevention

›Keep medications locked and out of reach

›Avoid mixing sedatives with alcohol or opioids

12References/r8

Clinical guidelines and consensus

›Core guidance sources

›American College of Medical Toxicology position statements on antidote use and toxicology consultation

›American Academy of Clinical Toxicology guidance on GI decontamination and activated charcoal

›Resuscitation council ACLS guidance for airway and hemodynamic instability management

Evidence based sources

›Key evidence base

›Reviews on flumazenil adverse events and seizure risk in mixed ingestion and benzodiazepine dependence

›Clinical toxicology textbooks on sedative hypnotic toxidromes and management

›Emergency medicine toxicology chapters on benzodiazepine and barbiturate overdose evaluation

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.